FDA OKs Second Gene Therapy for Hemophilia B
(MedPage Today) -- The FDA has approved a second gene therapy for adults with hemophilia B, drugmaker Pfizer announced on Friday.
The approval of fidanacogene elaparvovec (Beqvez) stipulates use in adult men with moderate to severe hemophilia...
Source: MedPage Today Public Health - Category: American Health Source Type: news
More News: American Health | Gene Therapy | Genetics | Haemophilia | Hemophilia | International Medicine & Public Health | Pfizer